Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048
Public ClinicalTrials.gov record NCT00157248. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Long-term, Open-label Follow-up Treatment of Patients With Atrial Fibrillation Who Have Been Previously Treated With BIBR 1048 in the PETRO Trial (Trial 1160.20 - NCT01227629). (PETRO Extension Trial: PETRO-Ex)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To determine the long term safety and efficacy of BIBR 1048 in patients with chronic atrial fibrilla tion, with or without concomitant chronic treatment with acetylsalicylic acid (ASA).
Study identification
- NCT ID
- NCT00157248
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 361 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2003
- Primary completion
- Dec 31, 2008
- Completion
- Not listed
- Last update posted
- May 18, 2014
Started 2003
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1160.42.10003 Boehringer Ingelheim Investigational Site | La Mesa | California | — | — |
| 1160.42.10006 Boehringer Ingelheim Investigational Site | Pensacola | Florida | — | — |
| 1160.42.10004 Boehringer Ingelheim Investigational Site | Port Charlotte | Florida | — | — |
| 1160.42.10002 Boehringer Ingelheim Investigational Site | St. Petersburg | Florida | — | — |
| 1160.42.10015 Boehringer Ingelheim Investigational Site | Baltimore | Maryland | — | — |
| 1160.42.10008 Boehringer Ingelheim Investigational Site | Westminster | Maryland | — | — |
| 1160.42.10012 Boehringer Ingelheim Investigational Site | Pittsfield | Massachusetts | — | — |
| 1160.42.10007 Boehringer Ingelheim Investigational Site | Troy | Michigan | — | — |
| 1160.42.10014 Boehringer Ingelheim Investigational Site | Hawthorne | New York | — | — |
| 1160.42.10013 Boehringer Ingelheim Investigational Site | New Hyde Park | New York | — | — |
| 1160.42.10009 Boehringer Ingelheim Investigational Site | North Durham | North Carolina | — | — |
| 1160.42.10001 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00157248, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 18, 2014 · Synced Sep 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00157248 live on ClinicalTrials.gov.